3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• Women who have received the 4th and 6th dose of zoledronic acid in study CZOL446H2301E1

Exclusion Criteria:

• Poor kidney, eye, liver health

• Use of certain therapies for osteoporosis in study CZOL446H2301E1

• Abnormal calcium levels

Other protocol-defined inclusion/exclusion criteria may apply